Development of CpG‐Depleted CFTR Plasmid‐Based Nanoparticles for Nonviral Gene Therapy in Lung Cystic Fibrosis Disease
The Journal of Gene Medicine · 2026-03 · 28 (3)
DOI: 10.1002/jgm.70087 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Gene Medicine, online erschienen am 23.03.2026. Verfasst von Bei Qiu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Charles Institute of Dermatology, School of Medicine, University College Dublin, Dublin, Ireland. Hauptthemen laut MEDLINE: Cystic Fibrosis Transmembrane Conductance Regulator, Cystic Fibrosis, Plasmids, Genetic Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Enterprise Ireland-Disruptive Technologies Innovation Fund (DTIF), Chinese Government-China Scholarship Council.
Abstract (Originalsprache)
Nonviral gene therapy holds promise as a potential treatment for lung cystic fibrosis (CF). However, the transient expression of the CF transmembrane conductance regulator (CFTR) protein has limited its clinical application. To circumvent this challenge, a CpG‐depleted CFTR plasmid was developed. The CpG‐depleted CFTR plasmid could be compacted into DNA nanoparticles and modified with the addition of highly branched poly(β‐amino ester)s (HPAEs), leading to an improved and sustained CFTR protein expression. Using a CpG‐depleted and codon‐optimized CFTR sequence, around 20‐fold increase in CFTR protein production was achieved 48 h after treatment, compared with healthy human bronchial epithelial cells (16HBE14o‐). To evaluate the duration of CFTR protein expression induced by the plasmid based on human elongation factor 1α (hEFIα) and cytomegalovirus (CMV) promoters, a time course study was conducted in human CF bronchial epithelial (CFBE14o‐) cells. hEFIα promoter revealed a remarkable 2.26‐fold increase in CFTR protein expression at 7 days after transfection compared with 16HBE14o‐ cells. This level of CFTR protein expression outperformed the commonly used CMV promoter. The in vitro results demonstrated that CpG‐depleted CFTR plasmid could be used to achieve high efficacy in subsequent in vivo evaluations, which, if validated, may provide promising prospects for the development of a novel and effective treatment for lung cystic fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Charles Institute of Dermatology, School of Medicine, University College Dublin, Dublin, Ireland.
- Centre for Regenerative Medicine, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK.
- Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.
- Institute of Precision Medicine (AUST-IPM), Anhui University of Science and Technology, Huainan, China.
- School of Public Health, Anhui University of Science and Technology, Huainan, China.
Förderung
- Enterprise Ireland-Disruptive Technologies Innovation Fund (DTIF)
- Chinese Government-China Scholarship Council
Zitieren
APA
Qiu, B., Lorino, M., Li, Y., He, Z., Wang, X., Wang, W., & Lara-Sáez, I. (2026). Development of CpG‐Depleted CFTR Plasmid‐Based Nanoparticles for Nonviral Gene Therapy in Lung Cystic Fibrosis Disease. The Journal of Gene Medicine, 28(3). https://doi.org/10.1002/jgm.70087
Vancouver
Qiu B, Lorino M, Li Y, He Z, Wang X, Wang W, et al. Development of CpG‐Depleted CFTR Plasmid‐Based Nanoparticles for Nonviral Gene Therapy in Lung Cystic Fibrosis Disease. The Journal of Gene Medicine. 2026;28(3). doi:10.1002/jgm.70087
BibTeX
@article{Qiu2026,
author = {Qiu, Bei and Lorino, Maryann and Li, Yinghao and He, Zhonglei and Wang, Xianqing and Wang, Wenxin and Lara-Sáez, Irene},
title = {Development of CpG‐Depleted CFTR Plasmid‐Based Nanoparticles for Nonviral Gene Therapy in Lung Cystic Fibrosis Disease},
journal = {The Journal of Gene Medicine},
year = {2026},
volume = {28},
number = {3},
doi = {10.1002/jgm.70087}
}
EUVIMED